Patent ID: 9597322
Date: 2017-03-21
CPC Classifications: A61K,A61P

Claim:
1. A method for treating non-ST elevation acute coronary syndrome in a patient planned to undergo coronary artery bypass grafting, the method comprising (a) administration of an effective amount of (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl) benzoylamino]-butyric acid methyl ester or a pharmaceutically acceptable salt thereof to the patient before the coronary artery bypass grafting, and then (b) stopping the administration of (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl) benzoylamino]-butyric acid methyl ester or the pharmaceutically acceptable salt thereof 3 or more and less than 6 hours prior to the coronary artery bypass grafting, wherein the administration of (2R,3R)-2-(3-carbamimidoyl-benzyl)-3-[4-(1-oxy-pyridin-4-yl) benzoylamino]-butyric acid methyl ester or the pharmaceutically acceptable salt thereof is in the form of an infusion dose in the range from 0.10 mg/Kg body weight/h to 0.14 mg/Kg body weight/h.